Severe renal toxicity due to intermediate-dose methotrexate
Methotrexate (MTX) is a drug widely used in the treatment of patients with malignant disease. Its well-known side effects include myelosuppression, mucositis and renal damage. These problems are primarily dose-related, tending to occur more frequently when high doses (greater than 1 g/m2) are given....
Gespeichert in:
| Veröffentlicht in: | Cancer chemotherapy and pharmacology 1989-10, Vol.24 (4), p.243-245 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 245 |
|---|---|
| container_issue | 4 |
| container_start_page | 243 |
| container_title | Cancer chemotherapy and pharmacology |
| container_volume | 24 |
| creator | STARK, A. N JACKSON, G CAREY, P. J ARFEEN, S PROCTOR, S. J |
| description | Methotrexate (MTX) is a drug widely used in the treatment of patients with malignant disease. Its well-known side effects include myelosuppression, mucositis and renal damage. These problems are primarily dose-related, tending to occur more frequently when high doses (greater than 1 g/m2) are given. We present four cases in whom severe renal and mucosal toxicity occurred with intermediate doses (200 mg/m2) of MTX despite folinic acid rescue. Possible reasons for this occurrence are discussed and means of avoiding such toxicity are suggested. Three of four patients developed severe loin pain within a few hours of injection; the significance of this symptom in relation to subsequent renal toxicity has implications for early recognition of the problem. |
| doi_str_mv | 10.1007/bf00257626 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF00257626</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2546688</sourcerecordid><originalsourceid>FETCH-LOGICAL-c377t-27449495f8063dce5694f7c174701d190a38ca9a9f21f03b1f3cdc670616b163</originalsourceid><addsrcrecordid>eNo9j0FLw0AQRhdRaqxevAs5eBKiszub3QRPWqwKBQ_2HjabWYykTdndSvvvjTT2NHzzPYZ5jF1zuOcA-qF2ACLXSqgTlnCJIoNC4ilLAKXMcg3ynF2E8A0AkiNO2ETkUqmiSNjjJ_2Qp9TT2nRp7HetbeM-bbY0hLRdR_IraloTKWv6QOmK4lcfPe2GzSU7c6YLdDXOKVvOX5azt2zx8fo-e1pkFrWOmdBSlrLMXQEKG0u5KqXTlmupgTe8BIOFNaUpneAOsOYObWOVBsVVzRVO2d3hrPV9CJ5ctfHtyvh9xaH686-e5__-A3xzgDfbenj8iI7CQ3879iZY0zlv1rYNR0xpJQUC_gJWC2Di</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Severe renal toxicity due to intermediate-dose methotrexate</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>STARK, A. N ; JACKSON, G ; CAREY, P. J ; ARFEEN, S ; PROCTOR, S. J</creator><creatorcontrib>STARK, A. N ; JACKSON, G ; CAREY, P. J ; ARFEEN, S ; PROCTOR, S. J</creatorcontrib><description>Methotrexate (MTX) is a drug widely used in the treatment of patients with malignant disease. Its well-known side effects include myelosuppression, mucositis and renal damage. These problems are primarily dose-related, tending to occur more frequently when high doses (greater than 1 g/m2) are given. We present four cases in whom severe renal and mucosal toxicity occurred with intermediate doses (200 mg/m2) of MTX despite folinic acid rescue. Possible reasons for this occurrence are discussed and means of avoiding such toxicity are suggested. Three of four patients developed severe loin pain within a few hours of injection; the significance of this symptom in relation to subsequent renal toxicity has implications for early recognition of the problem.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/bf00257626</identifier><identifier>PMID: 2546688</identifier><identifier>CODEN: CCPHDZ</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Adult ; Aged ; Back Pain ; Bicarbonates - therapeutic use ; Biological and medical sciences ; Drug toxicity and drugs side effects treatment ; Fluid Therapy ; Humans ; Hydrogen-Ion Concentration ; Kidney Diseases - chemically induced ; Kidney Diseases - prevention & control ; Kidney Diseases - urine ; Leucovorin - administration & dosage ; Leucovorin - therapeutic use ; Lymphoma, Non-Hodgkin - drug therapy ; Male ; Medical sciences ; Methotrexate - administration & dosage ; Methotrexate - adverse effects ; Middle Aged ; Mouth Mucosa ; Mouthwashes ; Pharmacology. Drug treatments ; Sodium - therapeutic use ; Sodium Bicarbonate ; Stomatitis - chemically induced ; Stomatitis - prevention & control ; Toxicity: urogenital system</subject><ispartof>Cancer chemotherapy and pharmacology, 1989-10, Vol.24 (4), p.243-245</ispartof><rights>1990 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c377t-27449495f8063dce5694f7c174701d190a38ca9a9f21f03b1f3cdc670616b163</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=6764230$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2546688$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>STARK, A. N</creatorcontrib><creatorcontrib>JACKSON, G</creatorcontrib><creatorcontrib>CAREY, P. J</creatorcontrib><creatorcontrib>ARFEEN, S</creatorcontrib><creatorcontrib>PROCTOR, S. J</creatorcontrib><title>Severe renal toxicity due to intermediate-dose methotrexate</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><description>Methotrexate (MTX) is a drug widely used in the treatment of patients with malignant disease. Its well-known side effects include myelosuppression, mucositis and renal damage. These problems are primarily dose-related, tending to occur more frequently when high doses (greater than 1 g/m2) are given. We present four cases in whom severe renal and mucosal toxicity occurred with intermediate doses (200 mg/m2) of MTX despite folinic acid rescue. Possible reasons for this occurrence are discussed and means of avoiding such toxicity are suggested. Three of four patients developed severe loin pain within a few hours of injection; the significance of this symptom in relation to subsequent renal toxicity has implications for early recognition of the problem.</description><subject>Adult</subject><subject>Aged</subject><subject>Back Pain</subject><subject>Bicarbonates - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Fluid Therapy</subject><subject>Humans</subject><subject>Hydrogen-Ion Concentration</subject><subject>Kidney Diseases - chemically induced</subject><subject>Kidney Diseases - prevention & control</subject><subject>Kidney Diseases - urine</subject><subject>Leucovorin - administration & dosage</subject><subject>Leucovorin - therapeutic use</subject><subject>Lymphoma, Non-Hodgkin - drug therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methotrexate - administration & dosage</subject><subject>Methotrexate - adverse effects</subject><subject>Middle Aged</subject><subject>Mouth Mucosa</subject><subject>Mouthwashes</subject><subject>Pharmacology. Drug treatments</subject><subject>Sodium - therapeutic use</subject><subject>Sodium Bicarbonate</subject><subject>Stomatitis - chemically induced</subject><subject>Stomatitis - prevention & control</subject><subject>Toxicity: urogenital system</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9j0FLw0AQRhdRaqxevAs5eBKiszub3QRPWqwKBQ_2HjabWYykTdndSvvvjTT2NHzzPYZ5jF1zuOcA-qF2ACLXSqgTlnCJIoNC4ilLAKXMcg3ynF2E8A0AkiNO2ETkUqmiSNjjJ_2Qp9TT2nRp7HetbeM-bbY0hLRdR_IraloTKWv6QOmK4lcfPe2GzSU7c6YLdDXOKVvOX5azt2zx8fo-e1pkFrWOmdBSlrLMXQEKG0u5KqXTlmupgTe8BIOFNaUpneAOsOYObWOVBsVVzRVO2d3hrPV9CJ5ctfHtyvh9xaH686-e5__-A3xzgDfbenj8iI7CQ3879iZY0zlv1rYNR0xpJQUC_gJWC2Di</recordid><startdate>198910</startdate><enddate>198910</enddate><creator>STARK, A. N</creator><creator>JACKSON, G</creator><creator>CAREY, P. J</creator><creator>ARFEEN, S</creator><creator>PROCTOR, S. J</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>198910</creationdate><title>Severe renal toxicity due to intermediate-dose methotrexate</title><author>STARK, A. N ; JACKSON, G ; CAREY, P. J ; ARFEEN, S ; PROCTOR, S. J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c377t-27449495f8063dce5694f7c174701d190a38ca9a9f21f03b1f3cdc670616b163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Back Pain</topic><topic>Bicarbonates - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Fluid Therapy</topic><topic>Humans</topic><topic>Hydrogen-Ion Concentration</topic><topic>Kidney Diseases - chemically induced</topic><topic>Kidney Diseases - prevention & control</topic><topic>Kidney Diseases - urine</topic><topic>Leucovorin - administration & dosage</topic><topic>Leucovorin - therapeutic use</topic><topic>Lymphoma, Non-Hodgkin - drug therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methotrexate - administration & dosage</topic><topic>Methotrexate - adverse effects</topic><topic>Middle Aged</topic><topic>Mouth Mucosa</topic><topic>Mouthwashes</topic><topic>Pharmacology. Drug treatments</topic><topic>Sodium - therapeutic use</topic><topic>Sodium Bicarbonate</topic><topic>Stomatitis - chemically induced</topic><topic>Stomatitis - prevention & control</topic><topic>Toxicity: urogenital system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>STARK, A. N</creatorcontrib><creatorcontrib>JACKSON, G</creatorcontrib><creatorcontrib>CAREY, P. J</creatorcontrib><creatorcontrib>ARFEEN, S</creatorcontrib><creatorcontrib>PROCTOR, S. J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>STARK, A. N</au><au>JACKSON, G</au><au>CAREY, P. J</au><au>ARFEEN, S</au><au>PROCTOR, S. J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Severe renal toxicity due to intermediate-dose methotrexate</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>1989-10</date><risdate>1989</risdate><volume>24</volume><issue>4</issue><spage>243</spage><epage>245</epage><pages>243-245</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><coden>CCPHDZ</coden><abstract>Methotrexate (MTX) is a drug widely used in the treatment of patients with malignant disease. Its well-known side effects include myelosuppression, mucositis and renal damage. These problems are primarily dose-related, tending to occur more frequently when high doses (greater than 1 g/m2) are given. We present four cases in whom severe renal and mucosal toxicity occurred with intermediate doses (200 mg/m2) of MTX despite folinic acid rescue. Possible reasons for this occurrence are discussed and means of avoiding such toxicity are suggested. Three of four patients developed severe loin pain within a few hours of injection; the significance of this symptom in relation to subsequent renal toxicity has implications for early recognition of the problem.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>2546688</pmid><doi>10.1007/bf00257626</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0344-5704 |
| ispartof | Cancer chemotherapy and pharmacology, 1989-10, Vol.24 (4), p.243-245 |
| issn | 0344-5704 1432-0843 |
| language | eng |
| recordid | cdi_crossref_primary_10_1007_BF00257626 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Back Pain Bicarbonates - therapeutic use Biological and medical sciences Drug toxicity and drugs side effects treatment Fluid Therapy Humans Hydrogen-Ion Concentration Kidney Diseases - chemically induced Kidney Diseases - prevention & control Kidney Diseases - urine Leucovorin - administration & dosage Leucovorin - therapeutic use Lymphoma, Non-Hodgkin - drug therapy Male Medical sciences Methotrexate - administration & dosage Methotrexate - adverse effects Middle Aged Mouth Mucosa Mouthwashes Pharmacology. Drug treatments Sodium - therapeutic use Sodium Bicarbonate Stomatitis - chemically induced Stomatitis - prevention & control Toxicity: urogenital system |
| title | Severe renal toxicity due to intermediate-dose methotrexate |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T16%3A33%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Severe%20renal%20toxicity%20due%20to%20intermediate-dose%20methotrexate&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=STARK,%20A.%20N&rft.date=1989-10&rft.volume=24&rft.issue=4&rft.spage=243&rft.epage=245&rft.pages=243-245&rft.issn=0344-5704&rft.eissn=1432-0843&rft.coden=CCPHDZ&rft_id=info:doi/10.1007/bf00257626&rft_dat=%3Cpubmed_cross%3E2546688%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/2546688&rfr_iscdi=true |